This study is testing a new medicine called CPI-0209 for patients with advanced solid tumors and lymphomas (types of cancer). CPI-0209 is a small molecule that blocks EZH2, a protein that is often found at high levels in cancers and can help the disease grow. The study has two parts: Phase 1 looks at how safe the medicine is and how much can be given without causing too many side effects. Phase 2 tests how well the medicine works against cancer.

People can join if they have certain kinds of cancer that have come back or are growing after treatment. They also need to be healthy enough to handle the study medicine. Important things to know:

• The study might require multiple visits to the study center.
• Participants might receive different doses of the medicine to find the best amount.
• There might be risks, like side effects, since this is a new treatment.